Literature DB >> 28229405

Compact Bone-Derived Multipotent Mesenchymal Stromal Cells (MSCs) for the Treatment of Sjogren's-like Disease in NOD Mice.

Ghada Abu Elghanam1,2, Younan Liu1, Saeed Khalili3, Dongdong Fang1, Simon D Tran4.   

Abstract

Compact bone (cortical or dense bone) is among the organs that contain multipotent mesenchymal stromal cells (MSCs). Unlike bone marrow plugs where MSCs were initially isolated, compact bone has minimal (amount of) hematopoietic cells and thus facilitates the MSCs isolation process. In vitro, MSCs from compact bone show multipotency and differentiation into mesenchymal tissues such as bone, adipose, and cartilage, under certain conditions. MSCs therapy has been promising in preclinical and clinical studies against autoimmune diseases. Not only can MSCs replace the lost tissue through their regenerative properties, but they can also control the autoimmune attacks by immunoregulatory cytokines. This protocol describes the use of compact bone-derived MSCs to preserve salivary function (saliva flow/output) in the NOD (nonobese diabetic) mouse model affected with Sjogren's-like disease.

Entities:  

Keywords:  Autoimmune diseases; Compact bone; Hyposalivation; MSCs; Mesenchymal stromal cells; Nonobese Diabetic (NOD) mouse; Saliva; Sjogren’s syndrome; Sjogren’s-like disease; Xerostomia

Mesh:

Substances:

Year:  2017        PMID: 28229405     DOI: 10.1007/978-1-4939-6756-8_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.

Authors:  Ghada Abughanam; Osama A Elkashty; Younan Liu; Mohammed O Bakkar; Simon D Tran
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

Review 2.  Mesenchymal Stem Cells in Primary Sjögren's Syndrome: Prospective and Challenges.

Authors:  Weiqian Chen; Ye Yu; Jilin Ma; Nancy Olsen; Jin Lin
Journal:  Stem Cells Int       Date:  2018-09-16       Impact factor: 5.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.